期刊
BASIC RESEARCH IN CARDIOLOGY
卷 113, 期 5, 页码 -出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00395-018-0692-z
关键词
Cardioprotection; Caspase-1; Ischemia/reperfusion injury; Myocardial infarction; P2Y(12) receptor antagonist; VX-765
资金
- National Institutes of Health [R01HL118334]
Patients with acute myocardial infarction receive a P2Y(12) receptor antagonist prior to reperfusion, a treatment that has reduced, but not eliminated, mortality, or heart failure. We tested whether the caspase-1 inhibitor VX-765 given at reperfusion (a requirement for clinical use) can provide sustained reduction of infarction and long-term preservation of ventricular function in a pre-clinical model of ischemia/reperfusion that had been treated with a P2Y(12) receptor antagonist. To address, the hypothesis open-chest rats were subjected to 60-min left coronary artery branch occlusion/120-min reperfusion. Vehicle or inhibitors were administered intravenously immediately before reperfusion. With vehicle only, 60.3 +/- 3.8% of the risk zone suffered infarction. Ticagrelor, a P2Y(12) antagonist, and VX-765 decreased infarct size to 42.8 +/- 3.3 and 29.2 +/- 4.9%, respectively. Combining ticagrelor with VX-765 further decreased infarction to 17.5 +/- 2.3%. Similar to recent clinical trials, combining ticagrelor and ischemic postconditioning did not result in additional cardioprotection. VX-765 plus another P2Y(12) antagonist, cangrelor, also decreased infarction and preserved ventricular function when reperfusion was increased to 3 days. In addition, VX-765 reduced infarction in blood-free, isolated rat hearts indicating at least a portion of injurious caspase-1 activation originates in cardiac tissue. While the pro-drug VX-765 only protected isolated hearts when started prior to ischemia, its active derivative VRT-043198 provided the same amount of protection when started at reperfusion, indicating that even in blood-free hearts, caspase-1 appears to exert its injury only at reperfusion. Moreover, VX-765 decreased circulating IL-1 beta, prevented loss of cardiac glycolytic enzymes, preserved mitochondrial complex I activity, and decreased release of lactate dehydrogenase, a marker of pyroptosis. Our results are the first demonstration of a clinical-grade drug given at reperfusion providing additional, sustained infarct size reduction when added to a P2Y(12) receptor antagonist.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据